U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H19F2N7O
Molecular Weight 399.3973
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of L-838417

SMILES

CN1N=CN=C1COC2=NN3C(C=C2C(C)(C)C)=NN=C3C4=CC(F)=CC=C4F

InChI

InChIKey=BQDUNOMMYOKHEP-UHFFFAOYSA-N
InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23664899

L-838,417 is a subtype-selective GABAA modulator, acting as a partial agonist at alpha2, alpha3 and alpha5 subtypes and an antagonist at the alpha1 subtype. L-838,417 displays anxiolytic effects in vivo and is used as a tool compound to study roles of GABAA subunits.

Originator

Curator's Comment: # Merck

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?
2006 Mar
Patents

Patents

Sample Use Guides

In the model of anxiety L-838,417 was dissolved in a (2-Hydroxypropyl)-beta-cyclodextrin solution and administered intraperitoneally (i.p.) at a volume of 2 ml/kg to male and female adolescent and adult SD rats. Anxiolytic effect of L-838,417 was demonstrated at doses 1-4 mg/kg.
Route of Administration: Intraperitoneal
In Vitro Use Guide
Curator's Comment: Methods from https://www.ncbi.nlm.nih.gov/pubmed/9185540
Electrophysiological experiments on were performed on Ltk- cells expressing human cDNA combinations a1b3g2s, a2b3g2s, a3b3g2s and a5b3g2s. Glass coverslips containing the cells in a monolayer culture were transferred to a chamber on the stage of an inverted microscope. Cells were perfused continuously with a solution containing (in mM): 124 NaCl, 2 KCl, 2 CaCl2, 1 MgCl2, 1.25 KH2PO4, 25 NaHCO3, and 11 d-glucose, pH 7.2, and observed with phase-contrast optics. Patch pipettes were pulled with an approximate tip diameter of 2 μm and a resistance of 4 MΩ with borosilicate glass and were filled with (in mM): 130 CsCl, 10 HEPES, 10 EGTA, and 3 Mg+-ATP, pH-adjusted to 7.3 with CsOH. Cells were patch-clamped in whole-cell mode with a List LM-EPC 7 patch-clamp amplifier. Drug solutions were applied by a double-barreled pipette assembly, which was controlled by a stepping motor attached to a Prior manipulator, enabling rapid equilibration around the cell. Increasing GABA concentrations were applied for 10 sec pulses with a 30 sec interval between applications.
Name Type Language
L-838417
Code English
1,2,4-TRIAZOLO(4,3-B)PYRIDAZINE, 3-(2,5-DIFLUOROPHENYL)-7-(1,1-DIMETHYLETHYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-
Systematic Name English
Code System Code Type Description
PUBCHEM
9908880
Created by admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
PRIMARY
FDA UNII
8CZO0970G3
Created by admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
PRIMARY
WIKIPEDIA
L-838,417
Created by admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID90432710
Created by admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
PRIMARY
CAS
286456-42-6
Created by admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
PRIMARY